Quest Diagnostics INC Form 4 insider transactions

Patrick Plewman, SVP at Quest Diagnostics, acquired 81 shares of common stock through a dividend reinvestment plan at a price of $164.423 per share.

Director Vicky B. Gregg acquired 68 shares of Quest Diagnostics through a dividend reinvestment plan at a price of $164.422 per share.

Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, acquired 25 shares of common stock through a dividend reinvestment plan.

Quest Diagnostics CEO James E. Davis sold a portion of his common stock holdings on April 2, 2025, under a pre-arranged Rule 10b5-1 sales plan.

Karthik Kuppusamy, SVP, Clinical Solutions at Quest Diagnostics, reported the sale of 2,555 shares of common stock at $170 per share on April 2, 2025, according to a Form 4 filing.

Director Lassiter Wright III reports acquisition of phantom stock units through elective deferrals and dividend reinvestment in Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors.

Director Timothy M. Ring reports acquisition of phantom stock units due to elective deferrals and dividend reinvestments in Quest Diagnostics Incorporated.

Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics, disposed of 162 shares of common stock to cover tax withholding obligations arising from the vesting of restricted stock units.

Mark Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, disposed of 256 shares of common stock to cover tax withholding obligations arising from vesting of restricted stock units.

Michael E. Prevoznik, SVP & General Counsel of Quest Diagnostics, reports the sale of 4,643 shares of common stock at $170 per share on March 17, 2025, and indirectly owns 5,641 shares through a 401(k)/SDCP.

Catherine T. Doherty, EVP of Regional Businesses at Quest Diagnostics, reported the sale of 5,370 shares of common stock on March 5, 2025, at a price of $174.13 per share.

Michael J. Deppe, SVP, Corp. Controller & CAO of Quest Diagnostics, reports acquisition and disposition of company stock related to vesting of restricted stock units and settlement of a performance stock award.

Catherine T. Doherty, EVP at Quest Diagnostics, reports the acquisition and disposal of company stock, including transactions to cover tax obligations and sales under a Rule 10b5-1 plan.

Quest Diagnostics CEO James E. Davis reports acquisition and disposition of company stock related to vesting of restricted stock units and settlement of performance stock awards.

Karthik Kuppusamy, SVP at Quest Diagnostics, reports acquisition and disposal of company stock related to vesting of restricted stock units and a performance stock award.

Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics, reports acquisition and disposition of company stock related to vesting of restricted stock units and settlement of a performance stock award.

Michael E. Prevoznik, SVP & General Counsel of Quest Diagnostics, reports the acquisition and disposal of company stock, including transactions to cover tax obligations and sales under a Rule 10b5-1 plan.

Mark Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, reports the acquisition and disposition of company stock related to a performance stock award.

Executive Vice President & CFO of Quest Diagnostics, Sam Samad, reports acquisition of shares through a performance share award and disposition of shares to cover tax obligations.

Executive Vice President & CFO of Quest Diagnostics, Sam Samad, reports disposing of shares to cover tax withholding obligations from vesting restricted stock units.

Quest Diagnostics CEO, James E. Davis, disposed of 2,966 shares of common stock to cover tax withholding obligations arising from the vesting of restricted stock units on February 26, 2025.

Michael E. Prevoznik, SVP & General Counsel of Quest Diagnostics, reports the disposition and acquisition of company stock, including transactions to cover tax obligations and sales under a Rule 10b5-1 plan.

Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics, disposed of 229 shares of common stock to cover tax withholding obligations arising from the vesting of restricted stock units.

Karthik Kuppusamy, SVP at Quest Diagnostics, disposed of shares to cover tax withholding obligations from vesting restricted stock units.

Catherine T. Doherty, EVP at Quest Diagnostics, sold shares to cover tax obligations and under a pre-arranged 10b5-1 sales plan.

Michael J. Deppe, SVP, Corp. Controller & CAO of Quest Diagnostics, disposed of shares to cover tax withholding obligations from vesting restricted stock units.

Mark Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, disposed of 214 shares of common stock on February 26, 2025, to cover tax withholding obligations arising from the vesting of restricted stock units.

Executive Vice President & CFO of Quest Diagnostics, Sam Samad, disposed of 1,031 shares of common stock to cover tax withholding obligations arising from the vesting of restricted stock units.

Michael Prevoznik, SVP & General Counsel of Quest Diagnostics, reports the disposition and acquisition of company stock, including sales under a Rule 10b5-1 plan and shares held in a 401(k)/SDCP.

Patrick Plewman, SVP at Quest Diagnostics, sold 320 shares of common stock on February 19, 2025, to cover tax withholding obligations.